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Summary
 
Hematopoietic stem cell (HSC) self-renewal is a complicated process, and its regulatory mech-
anisms are poorly understood. Previous studies have identified tumor necrosis factor (TNF)-
 
a
 
as a pleiotropic cytokine, which, among other actions, prevents various hematopoietic progen-
itor cells from proliferating and differentiating in vitro. However, its role in regulating long-
term repopulating HSCs in vivo has not been investigated. In this study, mice deficient for
the p55 or the p75 subunit of the TNF receptor were analyzed in a variety of hematopoietic
progenitor and stem cell assays. In older p55
 
2
 
/
 
2
 
 mice (
 
.
 
6 mo), we identified significant differ-
ences in their hematopoietic system compared with age-matched p75
 
2
 
/
 
2
 
 or wild-type counter-
parts. Increased marrow cellularity and increased numbers of myeloid and erythroid colony-
forming progenitor cells (CFCs), paralleled by elevated peripheral blood cell counts, were found
in p55-deficient mice. In contrast to the increased myeloid compartment, pre-B CFCs were
deficient in older p55
 
2
 
/
 
2
 
 mice. In addition, a fourfold decrease in the number of HSCs could
be demonstrated in a competitive repopulating assay. Secondary transplantations of marrow
cells from primary recipients of p55
 
2
 
/
 
2
 
 marrow revealed impaired self-renewal ability of p55-
deficient HSCs. These data show that, in vivo, signaling through the p55 subunit of the TNF
receptor is essential for regulating hematopoiesis at the stem cell level.
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T
 
umor necrosis factor (TNF)-
 
a
 
, originally identified for
its cytotoxic effect on certain murine tumors (1), is a
pleiotropic cytokine that plays a pivotal regulatory role in
immune and inflammatory responses (2). Its effects are me-
diated through two functionally distinct cell surface recep-
tors, designated as the p55 and the p75 TNFR (3). The ac-
tivities of TNF-
 
a
 
 are predominantly mediated by the p55
receptor, and it has been postulated that the role of the
p75 receptor is primarily to enhance signaling through the
p55 receptor by recruiting and delivering TNF-
 
a
 
 to the p55
receptor (4). However, p55 TNFR–independent signaling
through the p75 receptor has been implicated in thymocyte
proliferation, apoptosis of activated mature T cells, and var-
ious other host defense mechanisms (5–9). In hematopoie-
sis, TNF-
 
a
 
 has been shown to both inhibit and stimulate
proliferation, depending on the maturation stage of the cell
population and other cytokines involved (10–13). Besides
its direct effect on hematopoietic cells (10, 13), TNF-
 
a
 
 can
exert its influence indirectly through the upregulation of
other cytokine receptors (10, 14–17). Furthermore, TNF-
 
a
 
can stimulate other hematopoietic cells or cells of the mi-
croenvironment to produce cytokines involved in hemato-
poietic cell proliferation and/or differentiation (10, 17–24).
Hematopoietic stem cells (HSCs)
 
1
 
 are responsible for the
steady state continuous generation of lineage-committed
progenitor cells, which then give rise to the different types
of mature blood cells. In response to various stimuli in situ-
ations that require rapid generation of mature blood cells,
such as myeloablation, HSCs are able to increase the pro-
duction of progenitor cells dramatically (25, 26). Despite
the enormous dynamic proliferative nature of HSCs, the
incidence of malignant transformation or bone marrow
(BM) failure is very low, indicating that the proliferation of
these cells is under tight control. One of the control mech-
anisms is to prevent HSCs from entering the cell cycle. It
has been demonstrated that an autocrine production of
 
J.L.M. Ferrara and C.A. Sieff contributed equally to this paper.
 
1
 
Abbreviations used in this paper:
 
 BFU-E, erythroid burst-forming unit;
BM, bone marrow; CFC, colony-forming cell; CFU-GEMM, multilin-
eage CFU; CFU-G/M, granulocyte/macrophage CFU; CFU-S, CFU in
the spleen; CRU, competitive repopulating unit(s); HSC, hematopoietic
stem cell; Lin, lineage; PB, peripheral blood; PI, propidium iodide; SSC,
side scatter; WBC, white blood cell; WT, wild-type. 
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TGF-
 
b
 
 negatively regulates the cycling activity of early
hematopoietic progenitors (27–29), including HSCs (30).
TNF-
 
a
 
 has been shown to have a similar regulatory effect on
Sca-1
 
1
 
Lin
 
2
 
c-Kit
 
1
 
 murine cells in culture (31). Moreover,
TNF-
 
a
 
 cooperates with TGF-
 
b
 
 in suppressing the prolifera-
tion of primitive Lin
 
2
 
Thy-1
 
1
 
 progenitors of the mouse (32).
Although there is ample evidence to support the notion
that TNF-
 
a
 
 plays an inhibitory role in the regulation of
proliferation of primitive progenitors, little is known about
its activity on true long-term repopulating HSCs. Such
knowledge may be critical for ex vivo stem cell manipula-
tion protocols, e.g., gene therapy. The in vitro studies of the
effects of TNF-
 
a
 
 on HSCs have been limited by the diffi-
culty in obtaining functionally uniform populations of these
cells. However, the availability of mice lacking the p55 or
the p75 TNFR makes it possible to circumvent this prob-
lem. We have now studied the role of TNFR signaling in
HSCs by transplanting BM cells from wild-type (WT),
p55
 
2
 
/
 
2
 
, or p75
 
2
 
/
 
2
 
 donor mice into lethally irradiated re-
cipients and directly assessing the ability of the graft to re-
constitute all hematopoietic lineages long-term. Because the
turnover time of the HSC pool is approximated at 30 d or
more (33, 34), we hypothesized that lack of signaling
through a TNFR would likely appear later in life. There-
fore, we compared hematopoietic cell populations from old
and young knockout mice with that of age-matched WT
mice. Except for a higher number of myeloid colony-
forming cells (CFCs) in the BM of p55
 
2
 
/
 
2
 
 mice, we found
no significant differences in any aspect of hematopoiesis be-
tween knockout and WT mice at a young age (
 
,
 
3 mo). In
contrast, the BM of older p55
 
2
 
/
 
2
 
 mice (
 
.
 
6 mo) showed
significantly lower numbers of HSCs compared with WT
mice, whereas progenitor cells and the more mature cell
populations had increased in size. The only cell compart-
ment that did not increase was the B cell lineage. Thus,
these findings demonstrate an important role for signaling
through the p55 TNFR in maintaining the HSC pool.
 
Materials and Methods
 
Mouse Strains.
 
p55- and p75-deficient mice, originally supplied
by Immunex Corp. to J.L.M. Ferrara, and C57BL/6 WT animals
(The Jackson Laboratory) were bred and maintained at the Red-
stone Animal Facility of the Dana-Farber Cancer Institute.
Congenic Ly5.1
 
1
 
 C57BL/6 mice were purchased from the Na-
tional Institutes of Health. All animals were kept under microiso-
lators and provided with food and water ad libitum.
 
Cell Preparations.
 
To obtain peripheral blood (PB) samples, mice
were first anesthetized by metaphane inhalation. For white blood
cell (WBC) and RBC counts, the mice were terminally bled via a
cardiac puncture. The counts were performed on a Coulter MaxM.
A small blood sample was obtained by puncture of the venous si-
nus in the eye for analysis for the presence of Ly-5.2
 
1
 
 cells (see
below). BM cells were obtained by flushing both tibiae and femurs
of donor mice with PBS containing 2% FCS. The cell suspension
was layered on a cushion of FCS and washed once in PBS, 2% FCS.
Nucleated cells were counted with a hemocytometer. Assuming that
the cell content of a tibia is 
 
z
 
0.6 that of a femur (35), the total cell
number was divided by 3.2 to calculate the cell number per femur.
 
FACS
 
®
 
 Analysis and Cell Sorting.
 
To determine the presence
of the different lineages in the BM, cells were incubated on ice for
35 min with the FITC-conjugated lineage (Lin) markers B220
(RA3-6B2), Mac-1 (M1/70), Gr-1 (RB6-8C5), Ly-1 (53-7.3),
or PE-labeled Ter119 (PharMingen). Cells were then washed twice
with PBS, 2% FBS. During the last wash, the medium contained
propidium iodide (PI, 2 
 
m
 
g/ml; Sigma Chemical Co.) to stain the
dead cells. Cells were analyzed on a single laser FACScan™ (Bec-
ton Dickinson).
For purification, cells were labeled with a cocktail of mAbs, in-
cluding Sca-1, derivatized with cyanine 5 succinimidyl ester (a gift
from Dr. P. Lansdorp, Terry Fox Laboratory, Vancouver, Brit-
ish Columbia, Canada), FITC-labeled Lin markers, and (PE)-
conjugated c-Kit (2B8; PharMingen). Where indicated, CD34-
FITC (RAM34; PharMingen) was used to further subdivide the
Sca-1
 
1
 
Lin
 
2
 
/lo
 
c-Kit
 
1
 
 subpopulation into CD34
 
1
 
 and CD34
 
2
 
 cells.
A preenrichment step was included in the purification protocol
when cells were sorted; total BM cells were depleted of cells that
expressed mature Lin markers by magnetic separation according to
the manufacturer’s directions (StemCell Technologies). Multicolor
analysis to identify and sort Sca-1
 
1
 
Lin
 
2
 
/lo
 
c-Kit
 
1
 
 progenitor cells
was performed on a Coulter Epics
 
®
 
 Elite ESP.
To calculate the absolute number of each cell type per femur
(i.e., the different mature cell lineages and Sca-1
 
1
 
Lin
 
2
 
/lo
 
c-Kit
 
1
 
cells), the total number of cells per femur was multiplied by the
fraction of each cell population in total BM cells as obtained by
FACS
 
®
 
 analysis.
 
Cell Cycle Analysis.
 
Unseparated BM cells or highly purified
progenitor cells were fixed in ice-cold 80% ethanol and kept on
ice overnight. The next day, cells were spun down and washed
once in PBS with 0.1% Triton X-100. Cells were resuspended
in 0.5 ml PBS containing 50 
 
m
 
g/ml PI, incubated at 37
 
8
 
C for 30
min, and then kept on ice until analysis, which was within 1–2 h of
finishing the staining. The sample was analyzed on a Coulter
Epics
 
®
 
 XL analyzer.
 
In Vitro Assays for Clonogenic Cells.
 
To assay for erythroid
(BFU-E), granulocyte and/or macrophage (CFU-G/M), multi-
lineage (CFU-GEMM), and pre-B clonogenic progenitors, cells
were resuspended in IMDM containing 2% FCS. A portion of
the cell suspension was resuspended in methylcellulose containing
medium that was supplemented with the appropriate cytokines
(StemCell Technologies). Pre-B cell colonies were scored in situ
after 7 d of culture, the other colonies after 12–14 d of culture.
The number of each clonogenic progenitor per femur was calcu-
lated by multiplying the number of nucleated cells per femur
with the frequency of each progenitor, i.e., the number of re-
spective colonies counted divided by the number of cells plated
(5 
 
3
 
 10
 
4
 
 cells for the pre-B cell assay and 1.5 
 
3
 
 10
 
4
 
 cells for the
erythroid/myeloid colony assay).
 
In Vivo Assay for CFU in the Spleen and Competitive Repopulating
Units.
 
The BM content of CFU-S day 12 cells was determined
as originally described (36). In brief, 7 
 
3
 
 10
 
4
 
 unseparated BM
cells were injected into C57BL/6 recipients that were irradiated
with 950 cGy given in two equally split doses (5 h apart) from a
 
137
 
Cs source. The spleens were harvested 12 d later, and the macro-
scopic surface colonies were counted. The spleens of control ani-
mals that were irradiated but not transplanted with BM cells
showed none or one to two pin-point size colonies. This size of
colony was not included in the colony counts of the spleens from
test animals. The number of CFU-S per femur was calculated by
multiplying the number of nucleated cells per femur with the fre-
quency of CFU-S, i.e., number of colonies counted divided by
7 
 
3
 
 10
 
4
 
. 
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A slightly modified competitive repopulating units (CRU) as-
say was used to determine the number of HSCs in BM (37, 38). In
brief, varying doses of unseparated test cells (Ly5.2
 
1
 
) were injected
together with 1 
 
3
 
 10
 
5
 
 unseparated adult BM “helper” cells (Ly5.1
 
1
 
)
into lethally irradiated (as for CFU-S) recipients (Ly5.1
 
1
 
). The
allelic difference at the Ly5 locus between the recipient/helper
cells and the test cell population was used to follow hematopoietic
reconstitution from the test cells. 4, 8, and 16 wk after the trans-
plantation, a small blood sample was taken from each mouse and
analyzed for the presence of Ly5.2
 
1
 
 cells. A mouse was consid-
ered to be reconstituted by CRU present in the test cell popula-
tion (“positive”) when, 16 wk after the transplantation, 
 
.
 
1% of
the PB cells were Ly5.2
 
1
 
 and included both myeloid and lym-
phoid cells, as determined by their respective distinct side scatter
(SSC) properties. CRU frequencies for every type of BM tested
were calculated by analysis of the proportion of negative mice us-
ing Poisson statistics (39). The number of CRU per femur was
calculated by multiplying the number of nucleated cells per femur
with the frequency of CRU.
Some transplanted mice were used as donors for secondary BM
transplantations. Marrow cells from both femurs and tibiae were
isolated, and a proportion of these cells together with Ly5.1
 
1
 
helper cells was injected into three to five irradiated Ly5.1
 
1
 
 re-
cipients (analogous to a normal CRU assay).
 
Statistical Analysis.
 
The Student’s 
 
t
 
 test was used for the com-
parison of the mean of various hematological parameters from
WT animals with that from p55
 
2
 
/
 
2
 
 or p75
 
2
 
/
 
2
 
 animals, unless oth-
erwise stated.
 
Results
 
Young Mice Lacking a p55 TNFR Show an Increase in Myeloid
Progenitors in Their BM, but No Other Hematopoietic Differences.
 
Several assays were performed to assess the various lineages
and subpopulations of the hematopoietic system (Table I).
In young TNFR-deficient mice (
 
,
 
3 mo), the WBC and
RBC counts in the PB did not differ from those of WT
mice, nor did the relative contributions to the several my-
eloid and lymphoid lineages (data not shown). The PB indi-
ces were mirrored by similar BM cellularities in these three
strains of mice. Functional analysis of marrow cell suspen-
sions revealed a significantly higher number of myeloid
clonogenic cells in p55
 
2
 
/
 
2
 
 mice compared with WT mice
(
 
P
 
 
 
, 
 
0.01), but no significant differences were observed in the
number of erythroid and pre-B clonogenic cells, or CRU.
 
Old p55
 
2
 
/
 
2
 
 Mice Show Significant Differences in Their Hemato-
poietic System Compared with WT Mice.
 
We hypothesized
that an effect of perturbed TNFR signaling in HSCs may
only be measurable with increased age. Therefore, we per-
formed the same series of hematopoietic cell assays with
BM cells from older mice (
 
.
 
6 mo). Neither the WT nor the
p75
 
2
 
/
 
2
 
 mice showed any significant change with aging, aside
from the normalization of the WBC counts in p75
 
2
 
/
 
2
 
mice. In contrast, a profound disturbance of hematopoiesis in
older p55
 
2
 
/
 
2
 
 mice could be demonstrated (Table II). Nearly
twice as many WBCs were found in the blood (
 
P
 
 , 0.0005),
and this was paralleled by the BM cell counts (P , 0.005).
Moreover, FACS® analysis of the various mature lineages
(Fig. 1 A) showed a tendency to increased cell numbers in
all lineages except the B cell lineage. The same tendency was
observed for clonogenic progenitors (Fig. 1 B). When all
myeloid CFCs, i.e., BFU-E, CFU-G/M, and CFU-GEMM,
were combined, the total number of colonies in p552/2 mar-
row was shown to be significantly higher than in WT or
p752/2 marrow (P , 0.01): 128,000 6 38,300 vs. 85,400 6
25,000 and 78,300 6 28,000, respectively. To assess the status
of immature progenitors, we performed CFU-S day 12 assays
and immunolabeled BM cells to identify the Sca-11Lin2/lo
c-Kit11 subpopulation. Similar to the mature myeloid clono-
genic progenitors, the number of CFU-S day 12 in p552/2
BM cells was higher compared with WT (not significant)
and p752/2 (P , 0.03) BM cells: 2,700 6 500 vs. 2,100 6
260 and 1,700 6 450, respectively (Fig. 1 B). Fig. 2 depicts
a representative FACS® profile of BM cells showing the
parameters used to calculate the absolute number of Sca-11
Lin2/loc-Kit11 cells per femur. There is a considerably
larger, although not statistically significant subpopulation of
Table I. The Numbers of Various Hematopoietic Subpopulations 
in the Blood and Marrow of Young (,3 mo) p552/2 or p752/2 Mice 
Do Not Differ from Those of Young WT Mice
WT p552/2 p752/2
PB WBCs (3103/ml) 6.5 (2.3) 7.6 (2.1) 3.7 (0.9)*
PB RBCs (3106/ml) 7.7 (1.3) 8.4 (0.6) 7.5 (0.8)
BM cellularity 
(3106/femur) 15.6 (3.8) 16.8 (2.9) 16.0 (4.8)
BM CFCs (per femur)
BFU-E (3103) 6.6 (1.5) 5.4 (1.4) 4.4 (2.0)
CFU-G/M (3104) 6.8 (1.2) 9.4 (1.3)‡ 6.0 (0.8)
CFU-GEMM (3103) 3.0 (2.1) 2.8 (2.1) 3.2 (1.8)
Pre-B (3103) 31.7 (33.1) 9.4 (7.2) 21.6 (16.2)
CRU per femur 600 700 ND
(95% confidence interval) (250–1,450) (350–1,400)
The numbers indicating the blood and BM cell counts and CFCs rep-
resent the mean (6 SD) of three separate experiments. The CRU assay
was performed once.
*WT vs. p752/2, not significant; p552/2 vs. p752/2, P , 0.02.
‡WT vs. p552/2, P , 0.01.
Table II. Cell Counts of the Blood and Marrow from Old WT
and Knockout Mice (.6 mo) Reveal an Increased Cell Output in 
p552/2 Mice
WT p552/2 p752/2
PB WBCs (3103/ml) 5.5 (1.1) 9.4 (1.9)* 5.5 (1.1)
PB RBCs (3106/ml) 8.4 (0.7) 9.1 (0.5) 7.8 (0.4)
BM cellularity (3106/femur) 15.8 (2.2) 26.2 (5.9)‡ 15.9 (2.6)
Presented is the mean (6 SD) from four separate experiments.
*WT vs. p552/2, P , 0.0005.
‡WT vs. p552/2, P , 0.005.1496 Defect in Stem Cells of p55 TNFR–deficient Mice
Sca-11Lin2/loc-Kit11 cells in p552/2 BM compared with
WT or p752/2 BM: 11,300 6 4,800 vs. 4,800 6 2,200 and
5,200 6 2,400 cells, respectively. Since this subpopulation
includes long-term repopulating HSCs (40), this pheno-
typic finding may indicate an increase in the number of
HSCs in p552/2 BM. However, it has been clearly shown
that phenotype does not always predict function (38, 41).
Therefore, we performed competitive repopulating experi-
ments under limiting dilution conditions to determine the
number of CRU per femur (Table III). To our surprise, we
found a significant decrease in the frequency of CRU
among p552/2 BM cells compared with WT (P , 0.001).
When corrected for BM cellularity, this translated into a near
fourfold reduction of the absolute number of CRU in
p552/2 mice (350 vs. 1,275 in WT mice). Taken together,
Figure 1. The numbers of mature and clonogenic progenitor cells, ex-
cept pre-B cells, are increased in the BM from old p552/2 mice. (A) The
mature cell compartment was assayed by immunolabeling the marrow
cells with mAbs directed against mature lineage markers. (B) Clonogenic
progenitors were measured in vitro (methylcellulose assay) and in vivo
(CFU-S). For specific details, see Materials and Methods. The results rep-
resent the mean 6 SD of data combined from three separate experiments.
The values for WT cells are indicated by white bars, p552/2 cells by black
bars, and p752/2 cells by gray bars. For the purpose of resolution of the
other parameters shown in this figure, the observed values for Mac-11
cells, Gr-11 cells, and G/M CFCs are divided by 5, 5, and 10, respec-
tively.  *Significant compared with WT values: Ly-11, P , 0.002;
Ter1191, P , 0.05; pre-B (p552/2), P , 0.02; pre-B (p752/2), P , 0.05.
Figure 2. FACS® analysis of BM cells from old WT and knockout mice
reveals an enlarged Sca-11Lin2/loc-Kit11 compartment in p552/2 mice.
WT cells are shown in A and B, p552/2 in C and D, and p752/2 in E and
F. Viable cells with low SSC properties that express Sca-1 (indicated by
the rectangles in A, C, and E) were further analyzed for expression of ma-
ture Lin markers and c-Kit (B, D, and F). The proportion of primitive
Sca-11Lin2/loc-Kit11 cells in each mouse strain was calculated by multi-
plying the percentage of Sca-11 cells (rectangles in upper panel) by the
percentage of cells within the Sca-11 gate that showed high levels of c-Kit
expression but lacked the expression of mature Lin markers (rectangles in
the lower panel). Indicated below the profiles are the respective mean per-
centages (6 SD) of Sca-11Lin2/loc-Kit11 cells obtained from combining
the data from three to four separate experiments. In parentheses is shown
the range of the numbers of Sca-11Lin2/loc-Kit11 cells per femur.
Table III. Marrow Cells from Older p552/2 Mice Contain Fewer 
CRU Than BM Cells from Age-matched WT or p752/2 Mice
Donor
cells
Experi-
ment
HSCs
Frequency
(in total BM)
(95% confidence
interval)
Average no.
per femur
WT 1 1:12,500 (5,700–27,500) 1,000
2 1:12,200 (5,600–26,400) 1,550
p552/2* 1 1:55,100 (22,900–132,300) 300
2 1:70,700 (32,750–152,500) 400
p752/2 1 1:20,700 (7,250–59,000) 700
2 1:14,800 (7,000–31,400) 1,100
Graded doses of unseparated BM cells from each mouse strain were in-
jected into three groups of animals, five mice each. Presented are the
results from two separate experiments, analyzed 16 wk after transplan-
tation. For more details, see Materials and Methods.
*The combined data from p552/2 mice (i.e., CRU frequency of 1:64,200
[36,350–113,100]) compared with the combined data from WT mice
(i.e., CRU frequency of 1:12,350 [7,100–21,500]) are significantly dif-
ferent (x2 test; P , 0.001).1497 Rebel et al.
these data show a tendency with aging in p55-deficient
mice to increased sizes of most mature and immature he-
matopoietic (progenitor) cell populations, which could ex-
plain the overall increase in marrow cellularity found in
these animals. At the same time, the number of HSCs that
give rise to this variety of cell populations is reduced.
HSCs That Lack the p55 Receptor Display Impaired Prolifer-
ative and Self-renewal Abilities. To further elucidate the ex-
tent of the stem cell defect in old p552/2 mice, we analyzed
in detail the hematopoiesis of three sets of mice transplanted
with low numbers of BM cells (Fig. 3, and Table IV).
Groups 1 and 2 represent animals transplanted with 16,000
total BM cells (WT and p552/2, respectively). A compari-
son of their donor repopulation kinetics as measured at var-
ious time points after transplant illustrates a dramatic decline
in donor reconstitution over a 4-mo time period by p552/2
BM cells, whereas the donor reconstitution by WT cells
showed a slight increase over the same time period tested
(Fig. 3). 16 wk after transplantation, the level of donor cells
in recipients of p552/2 BM cells (group 2) was significantly
lower (P , 0.05) compared with that in recipients of WT
BM cells (group 1) (1.1 6 1.0 vs. 10.2 6 12.2, respec-
tively). The difference in repopulating ability between WT
and p552/2 HSCs becomes even more apparent when in-
dividual mice are analyzed (Table IV). Between 4 and 16
wk after the transplantation, Ly5.21 donor reconstitution
did not increase in any of the recipients of p552/2 (Ly5.21)
BM cells. In contrast, more than half of all the animals that
had received WT (Ly5.21) BM cells showed an increase in
Ly5.21 cells, by as much as 38% in one of the recipients.
Moreover, only 22% of the group 2 animals that were multi-
lineage reconstituted at week 4 remained so at week 16, com-
pared with nearly 80% of the animals in group 1 (Table IV).
Thus, when equal numbers of BM cells are transplanted,
the repopulating ability of p552/2 marrow cells is inferior
to that of WT cells. However, when the CRU frequencies
(Table III) were used to calculate the average number of
CRU received by individual transplanted animals (i.e., the
total number of cells transplanted divided by the frequency
of CRU), it was calculated that group 1 had received on
average 1 HSC, whereas group 2 had received on average
0.3 HSC. This could potentially explain, or at least contrib-
ute to, the observed differences. Therefore, we compared
group 1 WT mice with a group of mice that received on
Table IV. Analysis of the Changes in the Percentage of Donor-derived Nucleated Blood Cells in Recipients of WT or p552/2 Marrow Cells 
Identifies a Rapid Loss of Hematopoietic Reconstitution by p552/2 Cells
Group (n)
Transplanted cells Change in donor repopulation from week 4 to week 16‡
Donor
Total cell no.*
(HSC) Increase Decrease
Multilineage donor
repopulation
%§
mean 6 SD
(range) %§
mean 6 SD
(range) wk 4 (%)i wk 16 (%)i
1 (9) WT 16,000 (1) 55 11.3 6 15.4 45 7.5 6 5.5 100 78
(2.1–38.8) (2.2–14.2)
2 (9) p552/2 16,000 (0.3) 0 – 100 5.0 6 4.2 89 22
(0.1–13.7)
3 (10) p552/2 64,000 (1) 10 0.4 90 14.0 6 8.8 100 70
(3.5–34.3)
*Indicated are the total number of Ly5.21 BM cells transplanted per recipient. The average number of HSCs received per recipient is shown in parentheses.
‡Mice that showed a decrease in donor repopulation between weeks 4 and 16 were combined, and the mean of the decrease 6 SD was calculated.
The range of the values is shown in parentheses. The same was done with mice that showed an increase in donor repopulation. With “%” is indi-
cated the fraction of animals within a group that showed a decrease/increase in the level of §donor reconstitution or imultilineage reconstitution an-
alyzed at the indicated time points after transplantation.
Figure 3. Transplantation of p552/2 marrow cells into irradiated recip-
ients results in less donor repopulation than equal numbers of WT mar-
row cells. Depicted is the average percentage of donor-derived nucleated
blood cells (% Donor-Repopulation) at 4, 8, and 16 wk after the trans-
plantation in three groups of animals. Group 1 (d) recipients received
16,000 unseparated WT BM cells. Groups 2 (s) and 3 (j) received
p552/2 cells: group 2 16,000 cells per mouse, and group 3 64,000 cells
per mouse. *Significantly different from the WT value at the correspond-
ing time point, P , 0.01. ‡Significantly different from the WT value at
the corresponding time point, P , 0.05.1498 Defect in Stem Cells of p55 TNFR–deficient Mice
average 1 p552/2 HSC, equivalent to 64,000 total BM cells
(group 3). As expected, approximately the same number of
mice remained multilineage reconstituted after 16 wk (Table
IV; 78% in group 1 and 70% in group 3). However, al-
though 4 wk after the transplantation the level of donor re-
constitution in group 3 (p552/2 transplant) recipients was
significantly higher than in group 1 (WT transplant) recipi-
ents (P , 0.01), the percentage of donor p552/2 cells, again,
gradually decreased with each subsequent analysis (Fig. 3).
90% of all animals that received p552/2 marrow cells
showed as much as a 34% decline in donor reconstitution
(Table IV). Thus, not only does p552/2 marrow contain
fewer HSCs, these data also indicate that the proliferative
potential of p552/2 HSCs is less than that of WT HSCs.
To further stress the proliferative response of the Ly5.21
transplanted cells, BM cells of some of the primary recipi-
ents were transplanted into secondary recipients. The re-
sults of these experiments are shown in Table V. Eight
primary recipients of WT marrow cells and three of p752/2
marrow cells were used in these experiments. Because we
had not been able to demonstrate remarkable differences be-
tween WT and p752/2 hematopoiesis in older mice, we
grouped these mice together to compare their secondary
transplantation results to the results of the serially trans-
planted p552/2 marrow cells. Of 11 WT/p752/2 primary
recipients, 4 animals (36%) contained Ly5.21 HSCs that
generated multilineage progeny upon transplantation into
secondary recipients. This proportion is in accordance with
previous published data (42). Only 2 (18%) of the 11 pri-
mary recipients of p552/2 BM gave secondary reconstitu-
tion upon serial passage. As observed in the primary recipi-
ents of p552/2 cells, and in contrast to secondary recipients
of WT donor cells, the kinetics of Ly-5.21 reconstitution
in the secondary recipients showed a marked decline over
time (data not shown).
Cell Cycle Analysis of p552/2, p752/2, and WT BM Cells
Reveals No Gross Differences. One possible explanation for
the observed differences in HSC number and proliferative
potential between WT and p552/2 mice is a higher cycling
rate of p552/2 HSCs. Purified Sca-11Lin2/loc-Kit11 cells
still include large numbers of committed progenitor cells, as
confirmed by our finding that between 20 and 30% of these
cells (WT and knockout cells) were in the S/G2/M phase of
the cell cycle (data not shown). Therefore, we further subdi-
vided this population using an mAb against the CD34 anti-
gen. The Sca-11Lin2/loc-Kit11CD342 cells, which include
the long-term reconstituting HSCs (43), comprise z10% of
all Sca-11Lin2/loc-Kit11 cells. The sorting strategy for ob-
taining these cells is depicted in Fig. 4. The results of cell cy-
cle analyses of unseparated BM cells and highly purified cells
(box 3) are shown in Table VI. As expected, DNA staining
of unseparated BM cells did not demonstrate a difference in
cycling activity between the WT and either knockout
mouse. Moreover, the result obtained with the highly puri-
fied CD342 subpopulation of Sca-11Lin2/loc-Kit11 cells
isolated from p552/2 marrow cells did not strongly suggest
that cycling activity of p552/2 HSCs was altered. Therefore,
a difference in percentage of cycling HSCs does not seem to
explain the observed qualitative and quantitative differences
between HSCs from WT and p55-deficient mice.
Table V. Self-renewal in p552/2 HSCs Occurs Less Often Than in WT/p752/2 HSCs
Original
Ly5.21
donor cells
No. of primary
recipients used as
donors
No. of Ly5.21 cells
transplanted*
No. of primary recipients gener-
ating Ly5.21 progeny in secondary
recipients 20 wk after transplant
(average 6 SD of Ly5.21 cells)
(3105)
WT/p752/2 11 4.4 6 2.0 4 (8.8 6 8.9)
p552/2 11 5.4 6 2.2 2 (3.0 6 1.6)‡
*BM cells of primary recipients were harvested as usual and transplanted in three to five secondary recipients. The number of Ly5.21 (original) cells that was
injected per secondary recipient was calculated by multiplying the total number of BM cells injected with the percentage of Ly5.21 cells determined in the
blood by FACS® analysis. The difference between the number of cells transplanted from WT/p752/2 and p552/2 primary recipients is not significant.
‡The level of Ly5.21 reconstitution in the p552/2 secondary recipients is significantly different compared with the WT/p752/2 group; P , 0.03.
Figure 4. Purification strategy for isolating Sca-11Lin2/loc-Kit11
CD342 cells. Cells that express Sca-1 were identified as in the legend to
Fig. 2. Depicted are representative profiles of viable Sca-11 WT marrow
cells after lineage depletion. The Sca-11c-Kit11 cells, indicated by quad-
rants 1 and 2, showed no or low levels of mature Lin expression (A).
Thus, identifying Lin markers as a means to further purify “Lin-depleted”
Sca-11c-Kit11 cells is not very helpful. In contrast, replacing the mAb
cocktail directed against the Lin markers with an anti-CD34 mAb allows
the identification of a small subpopulation of the Sca-11Lin2/loc-Kit11
cells (z10%), the CD342 cells, that has been shown to include the long-
term repopulating HSCs (B, quadrant 3) (reference 43).1499 Rebel et al.
Discussion
The p55 and p75 TNFRs are ubiquitously expressed on
all hematopoietic cells, with the exception of erythroid and
unstimulated T cells (2, 44). There is ample evidence from
in vitro culture systems that, through one or both of these
receptors, TNF-a can promote the expansion and differen-
tiation of various hematopoietic subpopulations, as well
as inhibit their proliferative response (10–13). However,
the long-term effects of this cytokine in vivo as a possible
regulator of steady state hematopoiesis, especially with re-
gard to the stem cell compartment, are not well defined.
The present studies were undertaken to address this ques-
tion by analyzing the hematopoietic system of mice in which
TNF-a signaling is impaired. We and others (45) have
shown that most hematopoietic subpopulations tested are
present in young p552/2 and p752/2 mice at levels compa-
rable to those of WT mice. In older mice, no significant
differences in the assays tested between p752/2 and WT
mice could be demonstrated. However, when older p552/2
mice were compared with WT mice they showed an inter-
esting phenotype: their HSC compartment was significantly
smaller than that of their WT counterparts (approximately
fourfold), whereas the Sca-11Lin2/loc-Kit11 progenitor
compartment had increased in size (approximately two-
fold). This was reflected in significant increases in total cel-
lularity of the BM, total myeloid CFCs, and WBC and RBC
counts in the PB. Thus, with aging of the mice, the lack of
signaling through the p55 TNFR seems to affect the balance
between generating new HSCs (self-renewal) and produc-
ing committed progenitors (differentiation). Interestingly,
only the B cell lineage deviated from this pattern, in that
the numbers of B2201 cells in the marrow (Fig. 1 A) and in
the blood (data not shown) were similar to their WT coun-
terparts, whereas the number of pre-B CFCs was signifi-
cantly decreased in p55-deficient mice (Fig. 1 B). Previous
studies have shown that the p55 TNFR is essential for the
structural organization of lymphoid organs (46–49) and the
number of B cells in the Peyer’s patch (48). Our data also
suggest that the generation of B cells in the marrow de-
pends on p55 TNFR signaling. Whether this is mediated
by TNF-a or lymphotoxin a remains to be studied.
Exhaustion of the HSC pool can be explained by loss of
HSCs due to cell death or differentiation. TNF-a has been
shown to both induce and suppress apoptosis in murine
Sca-11Lin2 cells. Analogous to the effects of TNF-a on
the proliferation of hematopoietic cell populations, its ef-
fect on apoptosis seems to depend on which additional cy-
tokine was present: suppression in cultures with IL-1a
present, and induction when Steel factor was supplied (50).
The apoptotic effects of TNF-a are well documented and
mainly exerted through its p55 receptor (51, 52), although
an apoptotic role for the p75 receptor has been demon-
strated in mature CD81 cells (9). Increased apoptosis in
HSCs will definitely decrease the HSC pool. However, if
this were the case in p552/2 mice, one would expect to
find an accompanying decrease in the number of progeni-
tor cells. The opposite was found in our p55-deficient mice.
The mechanisms that control self-renewal versus commit-
ment decisions in HSCs are not known. However, it is
generally accepted that an increase in the number of HSC
cell divisions is accompanied by an increased chance of
HSCs to commit and differentiate among one of the lin-
eages (53–55). TNF-a has been shown to prevent WT but
not p552/2 Sca-11Lin2c-Kit1 cells from entry into S phase
(31). Increased cycling of p552/2 HSCs could explain our
results. However, we could not detect a difference in cell
cycle activity between Sca-11Lin2c-Kit1 subpopulations
(CD341 or CD342) sorted from WT or p552/2 BM cells.
The effects of TNF-a on the cell cycle of HSCs may be
very subtle, which would explain why HSCs in young
mice seem unaffected and why it is not detectable by the
methods used in this study. One study has demonstrated
the importance of TGF-b in maintaining HSCs in a quies-
cent, noncycling state in unperturbed steady state hemato-
poiesis (30). Since TNF-a cooperates with TGF to inhibit
the proliferation of primitive progenitor cells (32), it is not
inconceivable that more HSCs escape their quiescent state
when one of the inhibitory signals is missing.
There are two important considerations with respect to
the finding that the phenotype in p552/2 mice manifests
only with aging (.6 mo of age). First, TNF-a production
and TNF-a signaling cascades seem to change with aging.
Aged mice produce more TNF-a in response to LPS (56),
and T cells from older humans express more p55 but less
p75 TNFR subunits and are more susceptible to TNF-
a–induced apoptosis (57). It is possible that TNF-a signaling
in HSCs also changes with aging, and that any deficiencies
in this signaling pathway have greater consequences later in
life. It may be of interest to look at mice of 20 mo or older
since the number of cycling HSCs increases dramatically at
this age (58). Second, hematopoiesis during fetal and/or neo-
natal development, which is at that time expanding tre-
mendously, not only contains HSCs with properties differ-
ent from adult HSCs (42, 59), but is also probably regulated
differently than adult, steady state hematopoiesis (60). The
regulatory mechanisms of fetal/neonatal hematopoietic cells
may not depend on TNF-a signaling at all. This, in addition
to the possibility that older hematopoietic cells, and HSCs
in particular, may be more sensitive to TNF-a, could ex-
plain the lack of a phenotype in young p552/2 mice.
Thus, our findings suggest that, with age, a lack of signaling
Table VI. The Proportion of Total BM Cells and Sca-11Lin2/lo 
c-Kit11CD342 Cells in S/G2/M Phases of the Cell Cycle
WT p552/2 p752/2
Total BM cells* 19.6 (4.5) 19.0 (4.2) 20.1 (4.7)
Sca-11Lin2/loc-Kit11CD342‡ 2.3–8.6 9.4 9.2
The mice used for this analysis were all .6 mo.
*Shown are the mean values (6 SD) from the combined data of five
separate experiments.
‡10–20 mice were killed to obtain enough cells for a reliable PI DNA
analysis. With WT marrow, this was done twice; with p552/2 and p752/2
marrow, once.1500 Defect in Stem Cells of p55 TNFR–deficient Mice
through the p55 TNFR increases the number of committed
hematopoietic progenitors and their subsequent progeny at a
cost to the stem cell pool. The scarcity of secondary recip-
ients with multilineage p552/2 progeny confirms the lack
of self-renewal or exhaustion of p552/2 HSCs. However,
what is surprising and contrary to our expectations is the
lower level of multilineage reconstitution per HSC from
p552/2 donors compared with WT. The explanation for
this reduction may be that hematopoietic regeneration in
myeloablated recipients is different from both adult steady
state hematopoiesis and fetal/neonatal hematopoiesis. Al-
though little is known about the cytokines and other regu-
latory elements in the activation and/or recruitment of
transplanted HSCs, there are some important differences
compared with steady state hematopoiesis (61). One impor-
tant difference is that transplanted HSCs must home to an
appropriate microenvironment. It is possible that altered
TNF-a signaling affects the homing properties of p552/2
cells. In this regard, it is of interest that TNF-a can affect
the expression of CXC chemokine receptor 4 (62–64), a
chemokine receptor critical for murine BM engraftment
and regeneration as well as B cell development (65, 66).
Moreover, in our experimental design, the transplanted HSCs
are influenced by stress-induced environmental changes as-
sociated with the myeloablation of the recipient. Stress can
induce elevated levels of glucocorticoid hormones, which,
in synergy with other cytokines, make BM cells more sus-
ceptible to IL-1 through upregulation of the IL-1 recep-
tors, which favors myeloid differentiation (67, 68). A bene-
ficial effect of IL-1 may be the suppression of apoptosis.
However, for this effect to be delivered, the combination
of TNF-a may be essential (50). Therefore, it is possible
that p552/2 HSCs acquire elevated levels of IL-1 receptors
after transplantation but are more likely to differentiate
than their WT counterparts when they do not receive the
appropriate TNF signal. Thus, the loss of HSCs and all
other hematopoietic cell types after transplantation of p552/2
marrow cells may not necessarily reflect steady state hemato-
poiesis, but rather the inability of these cells to adequately
respond to extreme proliferative stimuli.
The need for intact TNFR signaling in HSCs during he-
matopoietic regeneration of a myeloablated recipient may
be more crucial for its survival than during steady state he-
matopoiesis. The G0/G1 arrest that TNF-a has been
shown to induce in Sca-11Lin2c-Kit1 cells may be imper-
ative in restraining the proliferative response of HSCs to
external stimuli and thereby preventing their extinction. In
this respect, it is of interest that in TNF2/2 mice it was
shown that TNF is important for the generation of an in-
flammatory response, but its presence was far more essential
in limiting the extent and duration of this response (69).
This possible regulatory role in limiting the number of cell
divisions in HSCs warrants further investigation, for exam-
ple in retroviral gene therapy protocols with HSCs as target
cells. Future studies of the role of TNF in steady state he-
matopoiesis should include the analysis of mice older than
20 mo and the generation of allophenic mice, which would
allow the tracking of HSC progeny over time, without
perturbing the hematopoietic system (70).
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